Clinical Trials Logo
  1. Home
  2. Rosacea
  3. NCT02292797
  4. Details
NCT02292797 Clinical Trial

Assessment of the Rosacea Prevalence in the General Population

Rosacea Clinical Trial

— RISE  

Official title:
Assessment of the Prevalence of Rosacea in the General Population

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02292797
Other study ID # RD.03.SPR.29104
Secondary ID
Status Completed
Phase N/A
First received October 14, 2014
Last updated November 14, 2014
Start date September 2013
Est. completion date February 2014

Study information
Verified date November 2014
Source Galderma
Contact n/a
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational

Clinical Trial Summary

Multi-centre interventional cross-sectional prevalence study Assessment of the Rosacea Prevalence in the General Population.

Description:

Primary objective:

Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Recruitment information / eligibility
Status Completed
Enrollment 6000
Est. completion date February 2014
Est. primary completion date February 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Part I

Inclusion Criteria:

The following subjects will be included in the study:

- Subjects aged 18 to 65 years old from the general population

- Subjects who are willing to complete the questionnaires

Part II

Inclusion Criteria:

The following subjects will be included in Part II of the study:

- Subjects who screened positive for rosacea during the first part of the study and selected by random method

- Subjects who gave their informed consent to participate in Part II of the study

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Other:
• Prevalence assessment
Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Galderma

Outcome
Type Measure Description Time frame Safety issue
Primary percentage of subjects with rosacea diagnosis confirmed estimation of the percentage of rosacea patients in the general population general population will be surveyed over an expected average duration of 6 months No
See also
  Status Clinical Trial Phase
Completed NCT05597462 - Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks Phase 1
Completed NCT02601963 - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea Phase 2
Completed NCT02249065 - Mirvaso in Use Study Phase 4
Completed NCT01659853 - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Phase 3
Completed NCT01426269 - Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo Phase 4
Completed NCT00991198 - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage Phase 2
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Recruiting NCT04108897 - Analysis of the Microbiome in Rosacea Early Phase 1
Completed NCT03872050 - Deep Phenotyping of Rosacea and Migraine
Recruiting NCT06033352 - Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea Phase 2
Completed NCT03263273 - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Phase 2
Completed NCT04508205 - CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes Phase 1
Completed NCT04508660 - CGB-400 for the Reduction of Facial Redness Phase 1
Completed NCT05094700 - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants N/A
Active, not recruiting NCT03211585 - EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA N/A
Completed NCT02576860 - Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Phase 3
Completed NCT02637232 - Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Completed NCT02576847 - Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Phase 3
Completed NCT02583009 - A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea Phase 2
Completed NCT01993446 - A Safety and Efficacy Study of DRM02 in Subjects With Rosacea Phase 2